In older patients with arthritis and no history of cardiovascular disease, chronic use of any non-steroidal anti-inflammatory drug appears safe from a cardiovascular and gastrointestinal stand-point, and regular, non-selective NSAIDs such as ibuprofen and diclofenac appear just as safe as the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib according to results the SCOT trial.
EMBARGO 31 August 2015 at 08:00 BST
STUDY NAME: The SCOT Trial
SESSION NAME: Hot Line III - Diabetes Mellitus/Pharmacology
The Standard care versus Celecoxib Outcome Trial (SCOT) was presented in a Hot Line session at ESC Congress 2015.
The large trial, which included more than 7-thousand subjects taking chronic, prescribed NSAIDs in a primary care setting, is strong evidence for the safety of these medications overall, in light of recent debate about whether COX-2 inhibitors might carry less gastrointestinal risk but more cardiovascular risk compared to non-selective NSAIDs (nsNSAIDs), said Professor Thomas M MacDonald, MD, principal investigator of the study, from the University of Dundee in Scotland.
“We found no difference between nsNSAIDs and celecoxib, with low cardiovascular and upper gastrointestinal adverse event rates overall,” he commented. “In our view, it seems unlikely that another trial of nsNSAIDs versus COX2 inhibitors in subjects free from cardiovascular disease will ever be done due to the low event rates in this population.”
The trial included primary care patients aged 60 years and more who were free from known cardiovascular disease and taking chronic nsNSAIDs for their osteoarthritis or rheumatoid arthritis.
Subjects were randomly assigned to continue their nsNSAID or switch to celecoxib and then followed for a median of three years. The primary endpoint was a cardiovascular composite of hospitalisation for non-fatal myocardial infarction, hospitalisation for other biomarker positive acute coronary syndrome, non-fatal stroke or cardiovascular death.
The main secondary outcome was hospitalisation or death for upper gastrointestinal ulcer complications such as bleeding, perforation or obstruction.
The study found no significant differences between groups for any of the outcomes, with the cardiovascular outcome occurring in 1.8 % of the celecoxib group and 2.2% of the nsNSAID group (hazard ratio1.12; P=0.50).
Ulcer-related upper gastrointestinal complications were also uncommon in both groups.
Serious adverse reactions occurred at a similar rate (5.2% in the celecoxib group versus 5.8% in the nsNSAID group), but there were significantly more non-serious adverse reactions in the celecoxib group than the nsNSAID group (22% versus 16.1%, P<0.001) and significantly more patients withdrew from celecoxib compared to nsNSAID treatment (50.9% versus 30.2%, P< 0.0001).
“The main reasons given for withdrawal from celecoxib were lack of efficacy, poor tolerability and adverse effects suggesting that celecoxib was not as potent or as well tolerated as nsNSAIDs,” commented Professor MacDonald.
“However, it is fair to say that there was a lot of adverse publicity about selective COX-2 inhibitors and also subjects who have been taking long term nsNSAIDs might less likely to stay on celecoxib,” he added.
“Overall, in subjects who do not have significant cardiovascular disease, taking nsNSAIDS or celecoxib does not appear to confer major risk of subsequent cardiovascular disease,” he concluded.
SOURCES OF FUNDING: The study was funded by Pfizer.
DISCLOSURES: Professor MacDonald had part of his university salary reimbursed by Pfizer in connection with the SCOT trial. In the last 5 years he has received honoraria for lectures and consulting from NiCox, Novartis and Astra Zeneca in relation to NSAID therapies and from other companies regarding other therapeutic areas. Dundee University’s Medicines Monitoring Unit holds research grants from Pfizer, Menarini, Novartis and Amgen.
ESC Press OfficeFor background information, please contact the ESC Press Office.For independent comment on site, please contact the ESC Spokesperson coordinator: +44 7785 467 947
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at email@example.com.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved